Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are u... Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2. Show more
Data of Blarcamesine confirm upstream SIGMAR1 activation Presented as Late Breaking Oral Communications at Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024 Oral, once daily...
ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition Miami, FL – October 23, 2024 -- InvestorsHub NewsWire – EmergingGrowth.com, a leading...
Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia Patients are...
ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management Commercial Drone market expected to grow at 23.7 CAGR (Compound Annual Growth Rate) through...
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today Commercial Drone market expected to grow at 23.7 CAGR (Compound Annual Growth Rate) through 2030 Miam...
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.725 | -7.88043478261 | 9.2 | 9.2 | 7.18 | 1466877 | 7.85617834 | CS |
| 4 | 3.075 | 56.9444444444 | 5.4 | 10.45 | 5.22 | 1621876 | 7.64716408 | CS |
| 12 | 2.555 | 43.1587837838 | 5.92 | 10.45 | 4.9301 | 976137 | 6.69914938 | CS |
| 26 | 4.065 | 92.1768707483 | 4.41 | 10.45 | 3.51 | 1050409 | 5.81403031 | CS |
| 52 | 1.4755 | 21.0800771484 | 6.9995 | 10.45 | 3.25 | 1203543 | 5.83067959 | CS |
| 156 | -11.882 | -58.3681288992 | 20.357 | 21.3 | 3.25 | 1161601 | 8.73976483 | CS |
| 260 | 6.025 | 245.918367347 | 2.45 | 31.5 | 2.2 | 1315875 | 10.41451361 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
